Rachel Ann Edquilang, NP
Nurse Practitioner · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Los Gatos Premier Medicine PC · 3 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Rachel Ann Edquilang’s office at (408) 358-7360 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$40,271
Medicare paid this office $40,271 for 115 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, denosumab, 1 mg | 12 | $20,952 | None |
| Return visit (30+ min) | 66 | $11,765 | $96 |
| Short return visit (20+ min) | 14 | $2,161 | $72 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $895 | $56 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 23 | $561 | $22 |
See all 7 services
| Injection, denosumab, 1 mg | 12 | $20,952 | None |
| Return visit (30+ min) | 66 | $11,765 | $96 |
| Short return visit (20+ min) | 14 | $2,161 | $72 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $895 | $56 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 23 | $561 | $22 |
| Injection of drug or substance under skin or into muscle | 20 | $364 | $12 |
| Insertion of needle into vein for collection of blood sample | 12 | $112 | $9 |
Who their Medicare patients are
115 Original Medicare patients in 2024. Average age 77 · Women 79% · Also on Medicaid 22% · Health risk score 1.23. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 37% · Depression 29% · Coronary heart disease 26% · Atrial fibrillation 26% · Heart failure 23% · Chronic kidney disease 20% · Dementia 16% · Cancer 13% · COPD 12% · Stroke 11%.
The office billed $91,541, Medicare allowed $54,390 and paid $40,271; for 1,334 services of 27 kinds; $21,171 of it was for drugs given in the office and $19,100 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 115 | 1,334 | 77 | 1.23 | $91,541 | $40,271 |
| 2023 | 156 | 1,272 | 77 | 1.76 | $98,749 | $49,954 |
| 2022 | 25 | 29 | 74 | 2.04 | $3,603 | $2,064 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 83 | $20,974 | $76 |
| Injection, denosumab, 1 mg | 12 | $14,706 | None |
| Return visit (30+ min) | 51 | $8,458 | $97 |
| Short return visit (20+ min) | 17 | $1,848 | $74 |
| Injection of drug or substance under skin or into muscle | 16 | $227 | $12 |
2022: 1 service
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 19 | $1,350 | $71 |
Medicaid work
$187 in 2024
Medicaid paid $187 for 15 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ NURSING FACILITY CARE MOD MDM 30 MINUTES | 15 | $187 |
| 2024 | 15 | 1 | 14 | $187 |
| 2023 | 108 | 1 | 18 | $280 |
| 2022 | 14 | 1 | 14 | $0 |
See the largest Medicaid services in earlier years
2023
| SBSQ NURSING FACILITY CARE MOD MDM 30 MINUTES | 108 | $280 |
2022
| SBSQ NURSING FACILITY CARE MOD MDM 30 MINUTES | 14 | $0 |
Drugs they prescribed that Part D paid
$80,681
Pharmacies billed $80,681 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 5% of their Part D prescriptions (36 of 783) in 2024. Above the middle of the specialty; the typical nurse practitioner clinician is at 0%.
666 generic and 100 brand-name prescriptions · $80,681 in drug cost · 61 antibiotic prescriptions to 50 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Zolpidem | 92 | $814 | $9 |
| Duloxetine | 15 | $623 | $42 |
| Famotidine | 16 | $394 | $25 |
| NP Thyroid | 12 | $359 | $30 |
| Levothyroxine | 22 | $318 | $14 |
See all 15 drugs
| Zolpidem | 92 | $814 | $9 |
| Duloxetine | 15 | $623 | $42 |
| Famotidine | 16 | $394 | $25 |
| NP Thyroid | 12 | $359 | $30 |
| Levothyroxine | 22 | $318 | $14 |
| Atorvastatin | 26 | $279 | $11 |
| Tramadol | 18 | $225 | $12 |
| Lisinopril | 14 | $137 | $10 |
| Lorazepam | 27 | $114 | $4 |
| Hydrocodone-Acetaminophen | 12 | $112 | $9 |
| Trazodone | 12 | $87 | $7 |
| Clonazepam | 25 | $86 | $3 |
| Azithromycin | 22 | $84 | $4 |
| Omeprazole | 13 | $37 | $3 |
| Alprazolam | 14 | $21 | $2 |
Year by year
| 2024 | 783 | 160 | 5% (36) | 13% | $80,681 |
| 2023 | 349 | 112 | 5% (16) | None | $35,855 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Duloxetine | 16 | $671 | $42 |
| Zolpidem | 38 | $512 | $13 |
| Lorazepam | 14 | $116 | $8 |
| Azithromycin | 14 | $95 | $7 |
| Clonazepam | 12 | $78 | $7 |
| Alprazolam | 13 | $28 | $2 |
Money from drug and device companies
$891 in 2025
| 2025 | 12 | 37 | None | $891 |
| 2024 | 14 | 51 | None | $1,269 |
| 2023 | 15 | 39 | None | $847 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma US | Veozah | $181 | 6 payments
|
| Pfizer | Nurtec Odt | $148 | 8 payments
|
| Lilly USA | Mounjaro | $87 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $84 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $77 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $73 | 3 payments
|
See all 37 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-18 | Farxiga | $23 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-12-11 | Kerendia | $24 |
| Pfizer | Meals · 2025-11-21 | Nurtec Odt | $12 |
| Astellas Pharma US | Education · 2025-11-10 | None | $70 |
| Amgen | Meals · 2025-11-06 | Otezla | $29 |
| Pfizer | Meals · 2025-10-30 | Paxlovid | $2 |
| Pfizer | Meals · 2025-10-30 | Paxlovid | $9 |
| Abbvie | Meals · 2025-10-24 | Qulipta | $34 |
| Amgen | Meals · 2025-10-16 | Evenity | $31 |
| Pfizer | Meals · 2025-10-10 | Nurtec Odt | $29 |
| Astellas Pharma US | Meals · 2025-10-07 | Veozah | $28 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-25 | Kerendia | $29 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-18 | Jardiance | $25 |
| Astellas Pharma US | Meals · 2025-09-17 | Veozah | $35 |
| Bausch Health US | Meals · 2025-09-16 | Aplenzin | $21 |
| Lilly USA | Meals · 2025-09-11 | Mounjaro | $29 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2025-09-04 | Rexulti | $21 |
| Abbvie | Meals · 2025-08-28 | Ubrelvy | $15 |
| Exact Sciences | Meals · 2025-08-28 | The Cologuard Plus Collection Kit | $21 |
| Pfizer | Meals · 2025-08-22 | Eliquis | $24 |
| Pfizer | Meals · 2025-07-31 | Nurtec Odt | $27 |
| GlaxoSmithKline | Meals · 2025-07-29 | Trelegy Ellipta | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-24 | Farxiga | $31 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-17 | Jardiance | $25 |
| Astellas Pharma US | Meals · 2025-07-15 | Veozah | $11 |
| Lilly USA | Meals · 2025-07-10 | Mounjaro | $20 |
| Pfizer | Meals · 2025-06-26 | Paxlovid | $25 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-22 | Jardiance | $34 |
| Astellas Pharma US | Meals · 2025-05-09 | Veozah | $31 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-01 | Kerendia | $21 |
| Pfizer | Meals · 2025-04-11 | Nurtec Odt | $20 |
| Lilly USA | Meals · 2025-04-03 | Mounjaro | $20 |
| Exact Sciences | Meals · 2025-03-21 | Cologuard Collection Kit | $35 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-14 | None | $23 |
| Lilly USA | Meals · 2025-03-06 | Mounjaro | $18 |
| Abbvie | Meals · 2025-03-04 | Qulipta | $17 |
| Astellas Pharma US | Meals · 2025-02-27 | Veozah | $7 |
See earlier years (2024, 2023)
2024: $1,269
| Abbvie | Qulipta | $396 | 16 payments
|
| Astellas Pharma US | Veozah | $237 | 8 payments
|
| Pfizer | Nurtec Odt | $141 | 6 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $133 | 6 payments
|
| Lundbeck | Vyepti | $65 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $51 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $48 | 2 payments
|
| Novo Nordisk | Wegovy | $47 | 2 payments
|
| GlaxoSmithKline | Arexvy | $32 | 1 payment
|
| IBSA Pharma | Tirosint | $31 | 2 payments
|
| Amgen | Otezla | $28 | 1 payment
|
| Lilly USA | Mounjaro | $25 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $19 | 1 payment
|
| Currax Pharmaceuticals | Contrave | $14 | 1 payment
|
2023: $847
| IBSA Pharma | Tirosint | $154 | 3 payments
|
| Abbvie | Qulipta | $133 | 10 payments
|
| Astellas Pharma US | Veozah | $90 | 4 payments
|
| Pfizer | Comirnaty | $82 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $69 | 3 payments
|
| Novo Nordisk | Ozempic | $68 | 4 payments
|
| Mylan Specialty L.P. | Yupelri | $54 | 2 payments
|
| Acella Pharmaceuticals | NP Thyroid 60 | $44 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $27 | 1 payment
|
| GlaxoSmithKline | Arexvy | $26 | 1 payment
|
| Amgen | Repatha | $25 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $23 | 1 payment
|
| Lilly USA | Mounjaro | $21 | 1 payment
|
| Radius Health | Tymlos | $16 | 1 payment
|
| Idorsia Pharmaceuticals US | Quviviq | $15 | 1 payment
|
Professional record
- NPI
- 1730899600
- Licence
- CA 95022408
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 14901 National Ave Ste 101, Los Gatos, CA, 95032
- NPI first listed
- 2022-12-01
- NPI last updated
- 2026-04-15
- NPI record certified
- 2026-04-15
This is when the NPI record was last certified, not a medical board exam.